Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: Two case reports

Carcinoembryonic antigen glypican-3 (GPC3) is expressed by >40% of ovarian clear cell carcinoma (CCC) and is a promising immunotherapeutic target. We previously reported the safety of and immunological and clinical responses to a GPC3-derived peptide vaccine in a phase I clinical trial of patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Shiro, Shibata, Kiyosumi, Kikkawa, Fumitaka, Nakatsura, Tetsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185885/
https://www.ncbi.nlm.nih.gov/pubmed/24252799
http://dx.doi.org/10.4161/hv.27217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185885/
https://www.ncbi.nlm.nih.gov/pubmed/24252799
http://dx.doi.org/10.4161/hv.27217

Ejemplares similares